modelSulfadiazineAndTrimethop
Extends from Pharmacolibrary.Drugs.ATC.J.J01EE02.
Information
| name: | SulfadiazineAndTrimethoprim | |
| ATC code: | J01EE02 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 18 | L |
| clearance: | 1.0 | L/h (sulfadiazine), 2.3 L/h (trimethoprim) |
| other parameters in model implementation | ||
Sulfadiazine and trimethoprim is a fixed-dose combination antimicrobial agent consisting of a sulfonamide (sulfadiazine) and a dihydrofolate reductase inhibitor (trimethoprim). The combination is used primarily in the treatment of infections caused by susceptible bacteria, including urinary tract infections, respiratory tract infections, and some protozoal infections such as toxoplasmosis. This combination is approved and used in clinical practice today, especially for toxoplasmosis.
Pharmacokinetics
General healthy adult volunteers, single oral dose, steady-state parameters reported for both components in population PK studies.
References
Swain O'Fallon, E, et al., & Gustafson, DL (2020). Pharmacokinetics of a sulfadiazine and trimethoprim suspension in neonatal foals. Journal of veterinary pharmacology and therapeutics None –. DOI:10.1111/jvp.12930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33289123
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)